Podcast Pearls
First-Generation TRK Inhibitors: Clinical Evidence and Indications

Download this short summary slideset based on the content from CCO podcast with experts discussing key clinical data informing FDA approvals and treatment sequencing with first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC.
George D. Demetri, MD
Alexander Drilon, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 632 KB
Released: October 15, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Updated data from the CheckMate 648 study of first-line nivolumab + either chemotherapy or ipilimumab for esophageal SCC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: February 2, 2023

Stacey Stein, MD, on systemic therapy for advanced hepatocellular carcinoma, including most recent clinical data on first-line and second-line treatment options in this Clinical Care Options (CCO) text module

Stacey Stein, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 1, 2023 Expired: January 31, 2024

Read expert advice about the importance of managing adjuvant abemaciclib adverse events in early breast cancer, from Clinical Care Options (CCO)

Julia LaBarbera, MSN, RN, AGACNP-BC Released: January 31, 2023

Mark Pegram, MD, and Sara Tolaney, MD, MPH, discuss treatment and optimal management approaches for patients with TNBC, from Clinical Care Options (CCO)

Mark Pegram, MD Sara Tolaney, MD, MPH Released: January 31, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings